Sales Growth YoY (Last 12 Months): Ironwood Pharmaceuticals, Inc. (IRWD)

Graphic logo of ironwoodpharma.com (IRWD)

Is it worth investing in Ironwood Pharmaceuticals (IRWD), a company implementing "green chemistry" principles to reduce production toxicity? The TTM annual sales growth rate provides the answer, where the 18.40 mark characterizes this parameter. The positive trend is based on the expanding market share of Linzess and new drugs for rare gastrointestinal pathologies. High margins are sustained by a powerful brand and an extensive distribution network.

IRWD Ironwood Pharmaceuticals, Inc. Sales Growth YoY (Last Twelve Months) (02/11/2024 - 11/19/2026)

ironwoodpharma.com (IRWD) - metric breakdowns and financial figures

- market value and analyst target forecast:
Fundamental company valuation:Ironwood Pharmaceuticals, Inc.
Manufactured product of Ironwood Pharmaceuticals

This indicator measures the dynamics of total revenue over the last twelve months relative to the same period last year, allowing for an assessment of the business's actual expansion speed. By analyzing the 12-month year-over-year revenue growth rate, an investor can gauge the commercialization efficiency of Ironwood Pharmaceuticals (IRWD) gastroenterology drugs and the success of its strategy to reduce costs through global partnerships and the development of an innovative pipeline.